We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Simple Blood Test Predicts Risk of Heart and Kidney Disease in Diabetics

By LabMedica International staff writers
Posted on 23 Aug 2023
Print article
Image: Four biomarkers are strongly predictive for development of heart and kidney issues in Type 2 diabetics (Photo courtesy of American Heart Association)
Image: Four biomarkers are strongly predictive for development of heart and kidney issues in Type 2 diabetics (Photo courtesy of American Heart Association)

Medical professionals routinely assess biomarkers to screen, diagnose, or manage specific health conditions. Prior investigations have indicated that levels of certain biomarkers might predict the onset and advancement of chronic kidney disease and cardiovascular events in individuals with Type 2 diabetes. Now, an analysis of a clinical trial involving over 2,500 people affected by Type 2 diabetes and kidney disease has revealed that elevated levels of four biomarkers hold strong potential for predicting heart and kidney issues. This discovery could pave the way for a simple blood test to predict the risk of progressive heart and kidney problems in individuals with both Type 2 diabetes and kidney disease.

Researchers at Harvard Medical School (Boston, MA, USA) examined biomarker data from blood samples collected from 2,627 participants in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial. The trial assessed the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor (SGLT2 inhibitor), on concentrations of four biomarkers at the study's start, one-year mark, and three-year mark. The four biomarkers were N-terminal pro–B-type natriuretic peptide, high-sensitivity cardiac troponin T, growth differentiation factor-15, and insulin-like growth factor binding protein 7. The researchers also explored each biomarker's prognostic value for varying degrees of kidney issues and the risk of death attributed to kidney disease or cardiovascular disease.

Participants were categorized as low, medium, or high risk. The analysis revealed those categorized as high risk exhibited significantly higher rates of progressive kidney failure and cardiovascular complications throughout the three-year duration of the study. The researchers found that elevated concentrations of each biomarker at the study's outset strongly correlated with the severity of heart and kidney problems among the participants. Notably, individuals taking canagliflozin displayed lower concentrations of each biomarker after one year and three years, in comparison to those taking a placebo. After one year, biomarker levels in canagliflozin recipients increased by 3% to 10%, whereas placebo recipients experienced an increase of 6% to 29%.

“High levels of certain biomarkers are indicators of heart and kidney complications and may help predict future risk of disease progression,” said lead author James Januzzi, M.D., the Hutter Family Professor of Medicine at Harvard Medical School. “Treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, lowered biomarker levels and reduced the risk of hospitalization for heart failure and other heart complications in people at the highest risk.”

Related Links:
Harvard Medical School 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.